
Presentations & Events
Spotlight on Recent Biodesix Presentations
December 2023 | CHEST Journal
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis Comparing Screen Detection, Sex, Smoking History, and Nodule Size
Authors:
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis Comparing Screen Detection, Sex, Smoking History, and Nodule Size
Authors:
November 2024 | ISPOR Europe 2024
Six healthcare economics poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix
Six healthcare economics poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix
November 2024 | AMP 2024 Annual Meeting & Expo | Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix
Droplet Digital™ PCR (ddPCR™) in Precision Oncology and MRD: Perspectives from the Trenches
Droplet Digital™ PCR (ddPCR™) in Precision Oncology and MRD: Perspectives from the Trenches
Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.
Upcoming Biodesix Presentations and Events
April 25 – 30, 2025 | Chicago, IL | AACR Annual Meeting
Presentation on April 28 @ 12:30 PM in Spotlight Theater A: Developing Multi-Modal MRD and ctDNA Tests for Use in Clinical Research: Droplet Digital PCR-Driven Mutation and Methylation Quantification, CTCs and Proteomics by Gary Pestano, Ph.D., Biodesix Chief Development Officer and other speakers. Sponsored by Bio-Rad.
May 6, 2025 | Denver, CO | 2025 Structural Biology, Biochemistry and Biophysics Symposium at the University of Colorado, Anschutz Campus May 16 – 21, 2025 | San Francisco, CA | ATS 2025 International Conference May 13 – 16, 2025 | Montreal, QC, Canada | ISPOR May 19, 2025 | San Francisco, CA | Society for Advanced Bronchoscopy at ATS May 30 – June 3, 2025 | Chicago, IL | 2025 ASCO Annual Meeting June 1 – 5, 2025 | Baltimore, MD | 73rd Conference on Mass Spectrometry and Allied Topics June 16 – 19, 2025 | Boston, MA | BIO 2025Panel Discussion on June 17 @ 11 AM: Advancing Innovative Risk-Stratification Tests that Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry with Robin Harper Cowie, Chief Financial Officer, Biodesix, and other speakers.
June 24, 2025 | Denver, CO | Mountain West BioLife SummitPresentation and panel hosted by Brianna Phillips, VP Quality & Regulatory, Biodesix
June 26 – 28, 2025 | Nashville, TN | 2nd Annual APAPP National Conference August 14 – 16, 2025 | Austin, TX | AABIP 6th Annual Conference September 22 – 25, 2025 | Boston, MA | 15th Annual World CB & CDx Summit October 9 – 11, 2025 | Denver, CO | Go2 2025 Centers of Excellence Summit October 19 – 22, 2025 | Chicago, IL | CHEST 2025 November 7 – 8, 2025 | Charlotte, NC | Atrium Health & SAB Lung Nodule ConferenceView Past Biodesix Presentations and Events
9th Annual Liquid Biopsy for Precision Oncology Summit
Panel Discussion moderated by Matthew Pink Vice President of Business Development, Biodesix: Harnessing MRD & ctDNA to Inform Clinical Trial Decision Making & Improve Dosage Regimens
Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Empowering Precision Oncology & MRD Monitoring through ctDNA & CTC Analysis – Sponsored by Bio-Rad Laboratories
Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations White Paper co-authored Gary Pestano, Ph.D., Chief Development Officer, Biodesix and Brianna Phillips, Vice President of Quality and Regulatory Affairs, Biodesix: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications
Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations White Paper co-authored Gary Pestano, Ph.D., Chief Development Officer, Biodesix and Brianna Phillips, Vice President of Quality and Regulatory Affairs, Biodesix: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications
AMP 2024 Annual Meeting & Expo
Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Droplet Digital PCR (ddPCR) in Precision Oncology and MRD: Perspectives from the Trenches
Poster Presentation by Leisa Jackson, Staff Scientist, Biodesix & Gary Pestano, Ph.D., Chief Development Officer, Biodesix: TT037 Development of a Clinical-Grade Droplet Digital PCR Workflow for Blood-Based Detection of Cancer Relevant miRNAs
Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.
ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix: EPH31: Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US) EPH93: Prevalence of Pulmonary Nodules (PNs) in 2020 During the Coronavirus Disease (COVID-19) Pandemic in the United States (US) EE438: Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective EPH208: Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US) EHP209: Incidence of Pulmonary Nodules (PNs) in 2019 in the United States (US) CO183: Clinical Impact Model for Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNs) From a Health System Perspective
AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics
ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix: EPH31: Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US) EPH93: Prevalence of Pulmonary Nodules (PNs) in 2020 During the Coronavirus Disease (COVID-19) Pandemic in the United States (US) EE438: Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective EPH208: Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US) EHP209: Incidence of Pulmonary Nodules (PNs) in 2019 in the United States (US) CO183: Clinical Impact Model for Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNs) From a Health System Perspective
AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics
CHEST 2024 Annual Meeting
CHEST Learning Theater Presentation by Sonali Sethi, MD, FCCP, Pulmonary Medicine, Cleveland Clinic and D. Kyle Hogarth, MD, FCCP, Professor of Medicine, University of Chicago: “Patient impact & case studies - the real-world value of biomarkers in lung nodule management”



Go2 for Lung Cancer Centers of Excellence (COE) Summit
Droplet Digital PCR World 2024 Asia Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences
Droplet Digital PCR World 2024 Asia Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences